LoadingLoadingLoading40 funds hold it · 2 straight earnings beats
No insider open-market trades in 90 days (SEC Form 4). Congress: both buying and selling, $6K to $90K in total in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 5, 2026
Period ending
Sep 30, 2026
Earnings per share
$1.51 expected
Estimates as of Nov 11, 2026
EPS expected
$1.15 to $1.36
Revenue expected
10 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 5, 2026 | $1.75est. $1.51 | +15.81%beat | $2.39BSEC filing | -1.3%from $2.42B |
| Jun 30, 2026Reported Aug 6, 2026 | $1.87est. $1.85 | +0.95%in line | $2.47Best. $2.51B-1.75% | -0.2%from $2.47B |
| Mar 31, 2026Reported May 7, 2026 | $1.53est. $1.62 | -5.28%miss | $2.26BCompany release | +2.9%from $2.20B |
| Dec 31, 2025Reported Feb 12, 2026 | $1.48est. $1.40 | +5.48%beat | $2.39BAlpha Vantage | +3.0%from $2.32B |
| Sep 30, 2025Reported Nov 4, 2025 | $1.70est. $1.62 | +4.94%beat | $2.42BSEC filing | +1.4%from $2.39B |
| Jun 30, 2025Reported Aug 5, 2025 | $1.76est. $1.61 | +9.32%beat | $2.47BSEC filing | +4.8%from $2.36B |
| Mar 31, 2025Reported May 6, 2025 | $1.48est. $1.40 | +5.71%beat | $2.20BSEC filing | +0.4%from $2.19B |
| Dec 31, 2024Reported Feb 13, 2025 | $1.40est. $1.36 | +2.94%beat | $2.32BAlpha Vantage | +4.7%from $2.21B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.39B | $2.26B | $2.47B | $2.39B |
| Cost of what it sold | $743.0M | $641.0M | $673.0M | $698.0M |
| Gross profit | $1.64B | $1.62B | $1.79B | $1.69B |
| What it spent | ||||
| Research and development | $199.0M | $180.0M | $173.0M | $174.0M |
| Sales and admin | $619.0M | $588.0M | $592.0M | $582.0M |
| Other operating costs | — | $31.0M | $93.0M | $74.0M |
| Total operating expenses | $818.0M | $799.0M | $858.0M | $830.0M |
| What was left | ||||
| Operating profit | $826.0M | $822.0M | $937.0M | $863.0M |
| Interest on debt | $57.0M | $62.0M | $61.0M | $62.0M |
| Profit before tax | $761.0M | $758.0M | $866.0M | $729.0M |
| Tax | $158.0M | $157.0M | $175.0M | $138.0M |
| Net profit | $603.0M | $601.0M | $691.0M | $591.0M |
| EBITDA | $939.0M | $939.0M | $1.05B | $910.0M |
This stock is trending upward.
Trend
Constructive
75 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Why this money manager is buying S&P Global and Berkshire Hathaway
BearishNov 6Zoetis Inc earnings beat by $0.24, revenue topped estimates
BullishNov 5Zoetis Q3FY26 Results: Adjusted EPS rises 3% to $1.75, guidance raised
Leans bullishNov 5Marea Therapeutics to present at major November investor conferences on new cardioendocrine drug developments
Leans bullishNov 5Hahn Capital Management LLC Makes New $4.49 Million Investment in Miami International Holdings, Inc. $MIAX
NeutralNov 5Freshpet, Inc. Announces Q3 2026 Financial Results in SEC 8-K Filing
NeutralNov 4Zoetis Inc. stock outperforms competitors on strong trading day
BullishNov 4(ZTS) Risk Channels and Responsive Allocation
Leans bullishNov 434 macro signals shaping ZTS right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
